{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:34:28Z","timestamp":1776922468219,"version":"3.51.2"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Safety Pharmacology Society (SPS)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.vascn.2017.02.021","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T02:47:05Z","timestamp":1487645225000},"page":"34-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice"],"prefix":"10.1016","volume":"86","author":[{"given":"Simon","family":"Authier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Pugsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Koerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Fermini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystle","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2017.02.021_bb0005","author":"Anonymous"},{"key":"10.1016\/j.vascn.2017.02.021_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vascn.2016.06.001","article-title":"Safety pharmacology investigations on the nervous system: An industry survey","volume":"81","author":"Authier","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.vascn.2010.06.005","article-title":"Arrhythmogenic liability screening in cardiovascular safety pharmacology: Commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies","volume":"62","author":"Authier","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vascn.2013.05.002","article-title":"Safety pharmacology investigations in toxicology studies: An industry survey","volume":"68","author":"Authier","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/smll.200600083","article-title":"Microchip technology for automated and parallel patch-clamp recording","volume":"2","author":"Br\u00fcggemann","year":"2006","journal-title":"Small"},{"key":"10.1016\/j.vascn.2017.02.021_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2016.02.181","article-title":"The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study","volume":"80","author":"Cavero","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/1056-8719(93)90023-8","article-title":"Arrhythmia models in the rat","volume":"29","author":"Cheung","year":"1993","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cger.2012.07.003","article-title":"Epidemiology of arrhythmias and conduction disorders in older adults","volume":"28","author":"Chow","year":"2012","journal-title":"Clinics in Geriatric Medicine"},{"key":"10.1016\/j.vascn.2017.02.021_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0050","series-title":"Drug discovery world","first-page":"45","article-title":"Automated patch clamping finally achieves high throughout!","author":"Comley","year":"2014"},{"key":"10.1016\/j.vascn.2017.02.021_bb0055","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1540-8159.1988.tb06016.x","article-title":"Torsade de pointes and other pause-induced ventricular tachycardias: The short-long-short sequence and early afterdepolarizations","volume":"11","author":"Cranefield","year":"1988","journal-title":"Pacing and Clinical Electrophysiology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pharmthera.2013.04.008","article-title":"The Lambeth conventions (II): Guidelines for the study of animal and human ventricular and supraventricular arrhythmias","volume":"139","author":"Curtis","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2017.02.021_bb0070","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/hrt.63.6.342","article-title":"QT dispersion: An indication of arrhythmia risk in patients with long QT intervals","volume":"63","author":"Day","year":"1990","journal-title":"British Heart Journal"},{"key":"10.1016\/j.vascn.2017.02.021_bb0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2017.02.021_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"Journal of Biomolecular Screening"},{"key":"10.1016\/j.vascn.2017.02.021_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vascn.2005.05.001","article-title":"Non-clinical evaluation of ventricular repolarization (ICH S7B): Results of an interim survey of international pharmaceutical companies","volume":"52","author":"Friedrichs","year":"2005","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vascn.2008.12.001","article-title":"Spontaneous cardiac arrhythmias recorded in three experimentally- and drug-naive laboratory species (canine, primate, swine) during standard pre-study screening","volume":"59","author":"Gauvin","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2017.02.021_bb0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/toxsci\/kft205","article-title":"Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model","volume":"136","author":"Guo","year":"2013","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2017.02.021_bb0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.2042-7158.1996.tb05944.x","article-title":"The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016","volume":"48","author":"Hagerty","year":"1996","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00656997","article-title":"Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches","volume":"391","author":"Hamill","year":"1981","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.vascn.2017.02.021_bb0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0008-6363(00)00310-2","article-title":"Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey","volume":"49","author":"Hammond","year":"2001","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2017.02.021_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.vascn.2013.05.005","article-title":"Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds","volume":"68","author":"Himmel","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0125","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/01.CIR.103.15.2004","article-title":"Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic","volume":"103","author":"Hondeghem","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.vascn.2017.02.021_bb0130","article-title":"Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative","author":"Huang","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0135","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1056\/NEJMra000650","article-title":"Sudden death due to cardiac arrhythmias","volume":"345","author":"Huikuri","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vascn.2017.02.021_bb0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2017.02.021_bb0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1056\/NEJM198501243120401","article-title":"Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy","volume":"312","author":"Kennedy","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vascn.2017.02.021_bb0150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.taap.2016.06.025","article-title":"Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility","volume":"305","author":"Kirby","year":"2016","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0155","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: Superior to the HERG model in predicting torsade de pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Scientific Reports"},{"key":"10.1016\/j.vascn.2017.02.021_bb0160","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0706894","article-title":"A rabbit Langendorff heart proarrhythmia model: Predictive value for clinical hazard identification and safety margins","volume":"149","author":"Lawrence","year":"2006","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/10606820308257","article-title":"Flip the tip: An automated, high quality, cost-effective patch clamp screen","volume":"9","author":"Lepple-Wienhues","year":"2003","journal-title":"Receptors & Channels"},{"key":"10.1016\/j.vascn.2017.02.021_bb0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vascn.2008.07.001","article-title":"Benchmarking safety pharmacology regulatory packages and best practice","volume":"58","author":"Lindgren","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk","volume":"91","author":"Mirams","year":"2011","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2017.02.021_bb0180","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1161\/CIRCULATIONAHA.112.000570","article-title":"Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays","volume":"128","author":"Navarrete","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.vascn.2017.02.021_bb0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/19336950.2015.1079675","article-title":"Novel screening techniques for ion channel targeting drugs","volume":"9","author":"Obergrussberger","year":"2015","journal-title":"Channels (Austin, Tex.)"},{"key":"10.1016\/j.vascn.2017.02.021_bb0190","first-page":"H1023","article-title":"Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species","volume":"302","author":"O'Hara","year":"2012","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1400142","article-title":"Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator","volume":"1","author":"Okada","year":"2015","journal-title":"Science Advances"},{"key":"10.1016\/j.vascn.2017.02.021_bb0200","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vascn.2005.07.002","article-title":"Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs","volume":"53","author":"Ollerstam","year":"2006","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1161\/CIRCEP.111.962043","article-title":"Sudden cardiac death in hypertrophic cardiomyopathy","volume":"6","author":"O'Mahony","year":"2013","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vascn.2013.03.007","article-title":"Translational pharmacokinetic\u2013pharmacodynamic modeling of QTc effects in dog and human","volume":"68","author":"Parkinson","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0215","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1476-5381.2009.00207.x","article-title":"An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk","volume":"159","author":"Pollard","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0220","first-page":"3","article-title":"Toward a new gold standard for early safety: Automated temperature-controlled hERG test on the PatchLiner","volume":"26","author":"Polonchuk","year":"2012","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0225","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/bjp.2008.280","article-title":"Principles of safety pharmacology","volume":"154","author":"Pugsley","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0230","first-page":"473","article-title":"Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011","volume":"176","author":"Qato","year":"2016","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.vascn.2017.02.021_bb0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.vascn.2013.03.001","article-title":"Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay","volume":"68","author":"Qu","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2017.02.021_bb0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/toxsci\/kfv128","article-title":"Proarrhythmia risk assessment in human induced pluripotent stem cell-derived cardiomyocytes using the maestro MEA platform","volume":"147","author":"Qu","year":"2015","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2017.02.021_bb0245","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2017.02.021_bb0250","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/europace\/euv320","article-title":"Human-based approaches to pharmacology and cardiology: An interdisciplinary and intersectorial workshop","volume":"18","author":"Rodriguez","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.vascn.2017.02.021_bb0255","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium","volume":"167","author":"Sager","year":"2014","journal-title":"American Heart Journal"},{"key":"10.1016\/j.vascn.2017.02.021_bb0260","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00228-016-2023-3","article-title":"Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist\/inverse agonist","volume":"72","author":"Shah","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1109\/TNB.2004.842471","article-title":"Microchip technology in ion-channel research","volume":"4","author":"Sigworth","year":"2005","journal-title":"IEEE Transactions on Nanobioscience"},{"key":"10.1016\/j.vascn.2017.02.021_bb0270","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0002-8703(97)70255-2","article-title":"QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates","volume":"133","author":"Stramba-Badiale","year":"1997","journal-title":"American Heart Journal"},{"key":"10.1016\/j.vascn.2017.02.021_bb0275","author":"US FDA"},{"key":"10.1016\/j.vascn.2017.02.021_bb0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1476-5381.2009.00547.x","article-title":"Reducing QT liability and proarrhythmic risk in drug discovery and development","volume":"159","author":"Valentin","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1476-5381.2009.00530.x","article-title":"Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines","volume":"159","author":"Valentin","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0290","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1111\/bph.13207","article-title":"Evaluation of QTc prolongation in animal and human studies: A qualitative assessment of nonclinical and clinical concordance based on the literature","volume":"172","author":"Vargas","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0295","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001615","article-title":"Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil","volume":"4","author":"Vicente","year":"2015","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.vascn.2017.02.021_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jelectrocard.2016.07.017","article-title":"Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs","author":"Vicente","year":"2016","journal-title":"Journal of Electrocardiology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1472-8206.2002.00099.x","article-title":"The application of in vitro methods to safety pharmacology","volume":"16","author":"Wakefield","year":"2002","journal-title":"Fundamental and Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1476-5381.2009.00395.x","article-title":"Integrated risk assessment and predictive value to humans of non-clinical repolarization assays","volume":"159","author":"Wallis","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0315","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/clc.4960220404","article-title":"Sudden death in dilated cardiomyopathy","volume":"22","author":"Wu","year":"1999","journal-title":"Clinical Cardiology"},{"key":"10.1016\/j.vascn.2017.02.021_bb0320","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophysics Journal"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871917300424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871917300424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:19Z","timestamp":1761004819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871917300424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":64,"alternative-id":["S1056871917300424"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2017.02.021","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2017.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}